Patents Assigned to Genentech
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20160122316
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 5, 2016
    Applicants: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Anti-HER antibodies
    Patent number: 9327035
    Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: May 3, 2016
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Lauric Haber, Gabriele Schaefer, Mark X. Sliwkowski
  • Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
    Patent number: 9328106
    Abstract: Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: May 3, 2016
    Assignee: GENENTECH, INC.
    Inventors: Jason Burch, Minghua Sun, Xiaojing Wang, Wesley Blackaby, Alastair James Hodges, Andrew Sharpe
  • 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors
    Patent number: 9328091
    Abstract: Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 3, 2016
    Assignees: GENENTECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Anna Leivers, Josef R. Bencsik, James F. Blake, Martin F. Hentemann, Nicholas C. Kallan, Jun Liang, Ian S. Mitchell, Stephen T. Schlachter, Eli M. Wallace, Rui Xu, Tony P. Tang
  • Heteroaryl pyridone and aza-pyridone amide compounds
    Patent number: 9326985
    Abstract: Heteroaryl pyridone and aza-pyridone amide compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: May 3, 2016
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Wendy Lee, Wendy B. Young
  • Anti-polyubiquitin antibodies
    Patent number: 9321844
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: April 26, 2016
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Vishva Dixit, Marissa L. Matsumoto
  • Mutant smoothened and methods of using the same
    Patent number: 9321823
    Abstract: The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: April 26, 2016
    Assignees: Genentech, Inc., Curis, Inc.
    Inventors: Frederic J. de Sauvage, Gerrit J.P. Dijkgraaf, Thomas Januario, Robert L. Yauch
  • Pyridyl inhibitors of hedgehog signalling
    Patent number: 9321761
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: April 26, 2016
    Assignees: CURIS, INC., GENENTECH, INC.
    Inventors: Janet L. Gunzner-Toste, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. LaLonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20160108113
    Abstract: The present invention relates to anti-alpha-synuclein (anti-?-synuclein) antibodies and methods of using the same.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 21, 2016
    Applicant: GENENTECH, INC.
    Inventors: Gai Ayalon, Till Maurer
  • Assays for detecting antibodies specific to therapeutic anti-IgE antibodies and their use in anaphylaxis
    Patent number: 9315583
    Abstract: The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: April 19, 2016
    Assignee: Genentech, Inc.
    Inventors: Saloumeh Fischer, Dana L. Baker, Henry B. Lowman, Gerald R. Nakamura
  • INHIBITORS OF IAP
    Publication number: 20160102119
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Applicant: GENENTECH, INC.
    Inventors: Frederick COHEN, Lewis J. GAZZARD, Vickie Hsiao-Wei TSUI, John A. FLYGARE
  • ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20160102146
    Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: September 17, 2015
    Publication date: April 14, 2016
    Applicant: GENENTECH, INC.
    Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
  • Process for making hydroxylated cyclopentylpyrimidine compounds
    Patent number: 9309204
    Abstract: The invention provides new processes for making and purifying hydroxylated cyclopenta[d]pyrimidine compounds, which are useful for the treatment of diseases such as cancer as AKT protein kinase inhibitors, including the compound (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: April 12, 2016
    Assignees: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, Keith L. Spencer, Peter J. Stengel
  • Pyrazolopyridine compounds, compositions and methods of use
    Patent number: 9309240
    Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: April 12, 2016
    Assignee: GENENTECH, INC.
    Inventors: Toby Blench, Simon Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven Magnuson, Vickie Tsui, Karen Williams, Birong Zhang
  • Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use
    Patent number: 9309265
    Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: April 12, 2016
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Steven Do, Richard Goldsmith, Tim Heffron, Aleksandr Kolesnikov, Steven Staben, Alan G. Olivero, Michael Siu, Daniel P. Sutherlin, Bing-Yan Zhu, Paul Goldsmith, Tracy Bayliss, Adrian Folkes, Neil Pegg
  • ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20160096893
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: September 11, 2015
    Publication date: April 7, 2016
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • METHODS AND COMPOSITIONS FOR DETECTING AUTOIMMUNE DISORDERS
    Publication number: 20160097098
    Abstract: The invention provides methods and compositions useful for detecting autoimmune disorders.
    Type: Application
    Filed: September 2, 2015
    Publication date: April 7, 2016
    Applicant: Genentech, Inc.
    Inventors: Alexander ABBAS, Barmak MODREK, Michael J. TOWNSEND
  • ALKYNYL ALCOHOLS AND METHODS OF USE
    Publication number: 20160096850
    Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: August 22, 2014
    Publication date: April 7, 2016
    Applicant: GENENTECH, INC.
    Inventors: Nicole Blaquiere, Georgette Castanedo, Jianwen A. Feng, Baihua Hu, Steven Staben, Po-wai Yuen, Guosheng Wu, Jason Burch
  • Benzyl sulfonamide derivatives as RORc modulators
    Patent number: 9302985
    Abstract: Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: April 5, 2016
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Olivier Rene, Monique Bodil van Niel, Stuart Ward
  • ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20160090378
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: December 9, 2015
    Publication date: March 31, 2016
    Applicant: Genentech, Inc.
    Inventors: Mehmet Kahraman, Steven P. Govek, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval